Artivion, Inc.
AORT- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000784199
In the last 90 days, Artivion, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $1.03B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Artivion, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 4 insiders, $2.60M in total
- Insiders trading
- 4
- Net value
- −$2.60M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Artivion, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Green Andrew M | SVP, Regulatory and Quality | 40,160 | Sep 11, 2026 | 4 |
| Mackin James P | President & CEO | 877,275 | Aug 20, 2026 | 8 |
| Berry Lance A | EVP, COO, CFO & Treasurer | 210,112 | Aug 17, 2026 | 4 |
| Holloway Jean F | SVP, General Counsel | 184,118 | Aug 12, 2026 | 8 |
| Semedo Anthony B. | Director | 6,325Indirect | Jun 4, 2026 | 2 |
| Ackerman Thomas F | Director | 157,472 | May 20, 2026 | 1 |
| Bullock James | Director | 76,223 | May 20, 2026 | 1 |
| Bevevino Daniel J | Director | 157,637 | May 20, 2026 | 1 |
| Burbank Jeffrey H | Director | 61,372 | May 20, 2026 | 1 |
| Salveson Jon W | Director | 137,416 | May 20, 2026 | 1 |
| Borgstrom Marna P | Director | 56,664 | May 20, 2026 | 1 |
| Hoff Elizabeth A | Director | 34,765 | May 20, 2026 | 2 |
| Horton Amy | VP, Chief Accounting Officer | 139,088 | Mar 4, 2026 | 8 |
| Davis John E | Chief Commercial Officer | 230,794 | Mar 4, 2026 | 7 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | 60,097 | Mar 4, 2026 | 7 |
| Getz Matthew A | VP, Human Resources | 34,116 | Aug 19, 2024 | 0 |
| Maney Rochelle L. | VP, Quality | 44,518 | Mar 14, 2024 | 0 |
| Tyrs Florian | VP, Global Operations | 21,558 | Feb 29, 2024 | 0 |
| Thomson Robert C | VP Research & Development | 13,291 | Feb 26, 2024 | 0 |
| Maier Dennis B | SVP, Operations | 34,724 | Jun 8, 2023 | 0 |
| Lee David Ashley | Executive VP, COO & CFO | 347,217 | Mar 3, 2023 | 0 |
| Barthold Franz Peter | VP, Research & Development | 32,516 | Nov 10, 2022 | 0 |
| Morgan Harvey | Director | 46,342Indirect | Aug 31, 2021 | 0 |
| McCall Ronald D | Director | 121,768 | Aug 26, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Mackin James PPresident & CEO | SSale | −17.9K | $37.78 | −$675.8K | −1.9%947.3K after | |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Berry Lance AEVP, COO, CFO & Treasurer | SSale | −6.32K | $37.78 | −$238.6K | −2.9%210.8K after | |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Davis John EChief Commercial Officer | SSale | −4.57K | $37.78 | −$172.8K | −1.9%230.8K after | |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Stanton Marshall S.SVP, Clinical & MD Affair | SSale | −2.15K | $37.78 | −$81.2K | −3.5%60.1K after | |
| Mar 4, 2026 (view filing) | Mar 3-4 | 1 day | Holloway Jean FSVP, General Counsel | SSale | −12.8K | $37.93 | −$485.7K | −6.5%185.1K after | 2 lots |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Horton AmyVP, Chief Accounting Officer | SSale | −901 | $37.78 | −$34.0K | −0.6%139.1K after | |
| Jun 15, 2026 (view filing) | Jun 11 | 4 days | Green Andrew MSVP, Regulatory and Quality | SSale | −44.0K | $20.70 | −$910.7K | −42.2%60.3K after | 2 lots10b5-1 |
| Aug 12, 2026 (view filing)5:51 PM ET | Aug 12 | Same day | Holloway Jean FSVP, General Counsel | SSale | −977 | $28.49 | −$27.8K | −0.5%184.1K after | |
| Aug 17, 2026 (view filing)3:17 PM ET | Aug 14 | 3 days | Berry Lance AEVP, COO, CFO & Treasurer | SSale | −715 | $28.55 | −$20.4K | −0.3%210.1K after | |
| Aug 17, 2026 (view filing)3:18 PM ET | Aug 14 | 3 days | Green Andrew MSVP, Regulatory and Quality | SSale | −616 | $28.55 | −$17.6K | −1.0%59.6K after | |
| Aug 20, 2026 (view filing)2:11 PM ET | Aug 19 | 1 day | Mackin James PPresident & CEO | SSale | −70.0K | $28.96 | −$2.03M | −7.4%877.3K after | |
| Sep 4, 2026 (view filing)2:15 PM ET | Sep 2-3 | 2 days | Green Andrew MSVP, Regulatory and Quality | SSale | −8.00K | $27.03 | −$216.3K | −13.4%51.6K after | 2 lots |
| Sep 11, 2026 (view filing)5:28 PM ET | Sep 10 | 1 day | Green Andrew MSVP, Regulatory and Quality | SSale | −11.5K | $24.97 | −$286.7K | −22.2%40.2K after |